Board of Directors June Meeting Highlights

Not pictured: Paneez Khoury, MD, MHSc, FAAAAI

The members of the AAAAI Board of Directors met June 5-7, 2026, in Washington, DC, to discuss current and future activities. Prior to the meeting, Board members spent time on Capitol Hill meeting with Congressional staff to discuss issues such as Medicare physician reimbursement, the Penicillin Allergy Verification & Evaluation Act, the Provider Reimbursement Stability Act, the Safe Step Act and Improving Seniors’ Timely Access to Care Act (prior authorization), and NIH/NIAID 2027 funding.

The members of the Board of Directors appreciate the work of AAAAI committee members and Chairs as they strive toward the AAAAI mission to advance the knowledge and practice of allergy, asthma and immunology for optimal patient care. Over the course of the meeting, several significant decisions were made. Here are the highlights:

Approvals

The announcement of the JACI: In Practice Editor-in-Chief search, the 2027 AAAAI Honorary Award recipients, and changes to the funding and definitions for travel scholarships were all approved. Funding was approved for the 2027 Chrysalis Project Program, the 2026-2027 Leadership Institute programs, and $240,000 for a new cycle of Environmental Health Equity Research Grants. The Board also approved participation in two joint projects – one on Telehealth and AI Wellness between the AAAAI Health Informatics, Technology & Education Committee (HITE) and The American College of Allergy, Asthma & Immunology (ACAAI), and a joint project with AAAAI, The World Allergy Organization (WAO) and the newly formed African Alliance for Allergy and Clinical Immunology (AFRICALLI) on education in Africa.

The AAAAI Foundation Board of Directors approved a new Lectureship to be announced at the 2027 AAAAI Annual Meeting and a 2026-2029 Strategic Plan with key areas including Lectureships, expanding and strengthening the Foundation donor base, and a long-term vision for fundraising. They also approved funding for a new software program that will aid in donor management and reporting.

Presidential Presentation

AAAAI President Carla M. Davis, MD, FAAAAI, shared updates on her presidential initiatives centered on advancing access to the allergy/immunology specialty.

Develop state-of-the-art accessibility and personalization through artificial intelligence (AI). The new AI Task Force, chaired by Nick Rider, DO, FAAAAI, has formed and will meet later in the summer to begin their work.
Create the AAAAI Collaborative Translational Mechanistic Research Seed Award to support highly innovative research on new diagnostics, therapeutics or mechanistic understandings of human disease: $400,000 in funding for up to two 1-year (renewable) Collaborative Translational Mechanistic Research Seed Awards was approved, along with the task force, chaired by Nora A. Barrett, MD, FAAAAI, that will manage the award.
Additional outreach to patient advocacy organizations and the expansion of future advocacy efforts.

Miscellaneous

A number of other projects and topics were discussed, including an in-depth review of the status of the current AAAAI Strategic Plan and updates from each division on objectives and the tactics used to reach their specific goals.

In addition, the three divisions of the Board of Directors—Education, Practice & Policy and Research & Training—met individually to discuss committee activities. The Education Division received funding for the 4th year of Discovery, and the Practice & Policy Division received funding for the RSLAAIS for their 2027 winter meeting. The Research & Training Division received approval for an updated AAAAI Clinician Educator Award, including an expansion in funding from $45,000 to $50,000, as well as an additional $200,000, for a total of $400,000 in funding for the AAAAI Bridge Funding Awards for Research Continuity.

What

The next Board of Directors meeting

When

November 6-8, 2026

Where

Washington, DC